/
Can the CanRisk tool be used in cases of Ductal Carcinoma-In-Situ (DCIS)?
Can the CanRisk tool be used in cases of Ductal Carcinoma-In-Situ (DCIS)?
- Tim Carver
- Alex Cunningham PhD (Unlicensed)
Owned by Tim Carver
Last updated: Apr 04, 2022 by Alex Cunningham PhD (Unlicensed)
Currently the tool should not be used to calculate the risk of a subsequent (invasive) breast cancer in someone who has DCIS.
DCIS is a risk factor for invasive breast cancer but the risk of invasive breast cancer depends on the type of treatment for DCIS. Neither history of DCIS nor treatment are currently considered in BOADICEA/CanRisk. As a result, BOADICEA/CanRisk should not be used to predict risks in women who have already had a DCIS diagnosis.
, multiple selections available,
Related content
Can the CanRisk Tool incorporate pathology information for a second (contralateral) breast cancer?
Can the CanRisk Tool incorporate pathology information for a second (contralateral) breast cancer?
More like this
Can the CanRisk Tool be used to estimate breast cancer risks for both breasts after a patient has developed a first breast cancer?
Can the CanRisk Tool be used to estimate breast cancer risks for both breasts after a patient has developed a first breast cancer?
More like this
What does the CanRisk Tool do?
What does the CanRisk Tool do?
More like this
Is there an upper limit on the ages at cancer diagnosis considered by the CanRisk Tool?
Is there an upper limit on the ages at cancer diagnosis considered by the CanRisk Tool?
More like this
Can contralateral breast cancer be included for male individuals in CanRisk?
Can contralateral breast cancer be included for male individuals in CanRisk?
More like this
Can I use the CanRisk Tool to estimate risks for populations outside Europe?
Can I use the CanRisk Tool to estimate risks for populations outside Europe?
More like this